Flurpiridaz

Flurpiridaz

SCHEMBL1628419

CC(C)(C)n1ncc(OCc2ccc(COCCF)cc2)c(Cl)c1=O

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.45
LMNA P02545 2/20 0.45
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
MEN1 O00255 1/20 0.45
GALR3 O60755 1/20 0.45
NR2F2 P24468 1/20 0.45
GPR183 P32249 1/20 0.45
KMT2A Q03164 1/20 0.45
GPR35 Q9HC97 1/20 0.45
HTT P42858 2/20 0.43
HPGD P15428 1/20 0.43
ATM Q13315 1/20 0.43
NPSR1 Q6W5P4 1/20 0.40
MAPK1 P28482 3/20 0.38
MAPK14 Q16539 5/20 0.38
GAA P10253 1/20 0.36
TSHR P16473 2/20 0.34
TP53 P04637 1/20 0.34
APP P05067 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Flurpiridaz F 18 SCHEMBL12453262 1.00 SMN1; SMN2 (0.45) SMN1; SMN2LMNANPC1RAB9AMEN1
SCHEMBL22249092 0.97 SMN1; SMN2 (0.43) SMN1; SMN2LMNANPC1RAB9AMEN1
SCHEMBL15566349 0.91 SMN1; SMN2 (0.49) SMN1; SMN2LMNANPC1RAB9AMEN1
Flurpiridaz SCHEMBL16901966 0.91 SMN1; SMN2 (0.42) SMN1; SMN2LMNANPC1RAB9AMEN1
SCHEMBL15596646 0.91 SMN1; SMN2 (0.42) SMN1; SMN2LMNANPC1RAB9AMEN1
SCHEMBL1629038 0.91 SMN1; SMN2 (0.45) SMN1; SMN2LMNANPC1RAB9AMEN1
SCHEMBL18672268 0.91 SMN1; SMN2 (0.46) SMN1; SMN2LMNANPC1RAB9AMEN1
SCHEMBL15596698 0.91 APP (0.48) SMN1; SMN2LMNANPC1RAB9AMEN1
SCHEMBL16998559 0.91 SMN1; SMN2 (0.41) SMN1; SMN2LMNANPC1RAB9AMEN1
SCHEMBL15565441 0.91 SMN1; SMN2 (0.41) SMN1; SMN2LMNANPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260124326-A1 USE OF CYCLODEXTRINS AS A RADIOSTABILIZER GE HEALTHCARE LTD (GB) 2026-05-07 US claimed
US-12527884-B2 Use of cyclodextrins as a radiostabilizer GE HEALTHCARE LIMITED (GB) 2026-01-20 US claimed
WO-2025226286-A1 SYSTEMS AND METHODS FOR SIMULTANEOUS IMAGING OF MULTIPLE POSITRON EMISSION TOMOGRAPHY (PET) TRACERS MULTIF UNCTIONAL IMAGING LLC (US) 2025-10-30 WO claimed
US-20250329024-A1 SYSTEMS AND METHODS FOR SIMULTANEOUS IMAGING OF MULTIPLE POSITRON EMISSION TOMOGRAPHY (PET) TRACERS MultiFunctional Imaging LLC (US) 2025-10-23 US claimed
US-20250312494-A1 METHOD FOR PREPARING AN [18F] RADIOLABELLED COMPOUND WITH LOW WATER CONTENT DURING LABELLING STEP GE HEALTHCARE INC (GB) 2025-10-09 US claimed
US-20250312782-A1 APPARATUS AND METHOD FOR SOLID PHASE EXTRACTION GE HEALTHCARE LTD (GB) 2025-10-09 US claimed
EP-4330662-B1 ANALYTICAL HPLC GE HEALTHCARE LTD (GB) 2025-09-03 EP claimed
US-20250232865-A1 SYSTEMS AND METHODS FOR IMAGE REGISTRATION GE Precision Healthcare LLC 2025-07-17 US claimed
EP-4585155-A1 SYSTEMS AND METHODS FOR IMAGE REGISTRATION GE Precision Healthcare LLC (US) 2025-07-16 EP claimed
CN-114555133-B Use of cyclodextrins as radiostabilizers 通用电气健康护理有限公司 2025-02-11 CN claimed
EP-4355715-A1 METHOD FOR PREPARING AN [18F] RADIOLABELLED COMPOUND WITH LOW WATER CONTENT DURING LABELLING STEP GE Healthcare Limited (GB) 2024-04-24 EP claimed
EP-4330662-A1 ANALYTICAL HPLC GE Healthcare Limited (GB) 2024-03-06 EP claimed
CN-117500773-A Method for preparing [18F ] radiolabelled compounds with low water content during the labelling step 通用电气健康护理有限公司 2024-02-02 CN claimed
CN-117222890-A Analytical HPLC 通用电气健康护理有限公司 2023-12-12 CN claimed
US-20220409752-A1 USE OF CYCLODEXTRINS AS A RADIOSTABILIZER GE HEALTHCARE LIMITED (GB) 2022-12-29 US claimed
WO-2022263594-A1 METHOD FOR PREPARING AN [18F] RADIOLABELLED COMPOUND WITH LOW WATER CONTENT DURING LABELLING STEP GE HEALTHCARE LIMITED (GB) 2022-12-22 WO claimed
WO-2022263592-A1 PREPARATION OF A PH-ADJUSTED ASCORBIC ACID SOLUTION GE HEALTHCARE LIMITED (GB) 2022-12-22 WO claimed
WO-2022229155-A1 ANALYTICAL HPLC GE HEALTHCARE LIMITED (GB) 2022-11-03 WO claimed
EP-4048323-A1 USE OF CYCLODEXTRINS AS A RADIOSTABILIZER GE Healthcare Limited (GB) 2022-08-31 EP claimed
CN-114555133-A Use of cyclodextrins as radiostabilizers 通用电气健康护理有限公司 2022-05-27 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260124326-A1 USE OF CYCLODEXTRINS AS A RADIOSTABILIZER SLC7A11, BTD, PGD SMN1; SMN2 4284/4885LMNA 3314/4885NPC1 1535/4885
US-20220409752-A1 USE OF CYCLODEXTRINS AS A RADIOSTABILIZER SLC7A11, TBCA, GYPA SMN1; SMN2 4640/4885LMNA 3471/4885NPC1 3012/4885
US-20250312494-A1 METHOD FOR PREPARING AN [18F] RADIOLABELLED COMPOUND WITH LOW WATER CONTENT DURING LABELLING STEP AQP1, AQP3, TMEM14C SMN1; SMN2 4660/4885LMNA 2637/4885NPC1 322/4885
US-12527884-B2 Use of cyclodextrins as a radiostabilizer BTD, SLC7A11, PGD SMN1; SMN2 4542/4885LMNA 3667/4885NPC1 1459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.